MARKET

DVAX

DVAX

Dynavax Technolo
NASDAQ
12.41
0.00
0.00%
After Hours: 12.40 -0.01 -0.08% 19:59 03/28 EDT
OPEN
12.39
PREV CLOSE
12.41
HIGH
12.52
LOW
12.34
VOLUME
1.53M
TURNOVER
0
52 WEEK HIGH
15.15
52 WEEK LOW
9.48
MARKET CAP
1.62B
P/E (TTM)
-250.2016
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at DVAX last week (0318-0322)?
Weekly Report · 3d ago
Dynavax Technologies: Still A Believer
Dynavax Technologies Corporation's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with potential sales reaching $400 million by FY27. Shares of vaccine maker Dynavax continue to trade at the lower end of their range. With positive prospects and a strong balance sheet, the company presents a solid long-term investment opportunity.
Seeking Alpha · 4d ago
Dynavax: Holding Firm Despite Its Missing Cash Cow
Pandemic era CpG 1018 revenues are gone and unlikely to rekindle. HEPLISAV-B revenues create a reliable growing stream of income for Dynavax. The company is fairly valued at $1.92 billion. Cpg 1018 adjuvant is no longer viable as an independent source of revenue.
Seeking Alpha · 5d ago
Dynavax (NASDAQ:DVAX) Offers Potentially Robust Growth at a Rich Valuation
TipRanks · 03/19 14:09
Weekly Report: what happened at DVAX last week (0311-0315)?
Weekly Report · 03/18 09:28
Dynavax Secures New Sublease Agreement Amidst Zymergen’s Bankruptcy
TipRanks · 03/12 20:26
Weekly Report: what happened at DVAX last week (0304-0308)?
Weekly Report · 03/11 09:27
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Dynavax Technologies Corporation (NASDAQ:DVAX) has debt on its balance sheet. The company has US$222.7m of debt, but also has a net cash position of US$742.3m. In the last year it shrunk its revenue by 68% to US$232m. We don't think the company is too risky in the near term. The future profitability of the company will determine its future.
Simply Wall St · 03/06 17:14
More
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Webull offers Dynavax Technologies Corp stock information, including NASDAQ: DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.